160 related articles for article (PubMed ID: 32311417)
1. Targeting MerTK Enhances Adaptive Immune Responses After Radiation Therapy.
Tormoen GW; Blair TC; Bambina S; Kramer G; Baird J; Rahmani R; Holland JM; McCarty OJT; Baine MJ; Verma V; Nabavizadeh N; Gough MJ; Crittenden M
Int J Radiat Oncol Biol Phys; 2020 Sep; 108(1):93-103. PubMed ID: 32311417
[TBL] [Abstract][Full Text] [Related]
2. Triple Therapy with MerTK and PD1 Inhibition Plus Radiotherapy Promotes Abscopal Antitumor Immune Responses.
Caetano MS; Younes AI; Barsoumian HB; Quigley M; Menon H; Gao C; Spires T; Reilly TP; Cadena AP; Cushman TR; Schoenhals JE; Li A; Nguyen QN; Cortez MA; Welsh JW
Clin Cancer Res; 2019 Dec; 25(24):7576-7584. PubMed ID: 31540976
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of MER proto-oncogene tyrosine kinase by an antisense oligonucleotide enhances treatment efficacy of immunoradiotherapy.
Hu Y; Revenko A; Barsoumian H; Bertolet G; Fowlkes NW; Maazi H; Green MM; He K; Sezen D; Voss TA; Leyton CSK; Masrorpour F; Rafiq Z; Puebla-Osorio N; Leuschner C; MacLeod R; Cortez MA; Welsh JW
J Exp Clin Cancer Res; 2024 Mar; 43(1):70. PubMed ID: 38443968
[TBL] [Abstract][Full Text] [Related]
4. Mertk on tumor macrophages is a therapeutic target to prevent tumor recurrence following radiation therapy.
Crittenden MR; Baird J; Friedman D; Savage T; Uhde L; Alice A; Cottam B; Young K; Newell P; Nguyen C; Bambina S; Kramer G; Akporiaye E; Malecka A; Jackson A; Gough MJ
Oncotarget; 2016 Nov; 7(48):78653-78666. PubMed ID: 27602953
[TBL] [Abstract][Full Text] [Related]
5. AXL and MERTK receptor tyrosine kinases inhibition protects against pancreatic necrosis via selectively limiting CXCL2-related neutrophil infiltration.
Bao J; Zhang X; Li B; Niu M; Wu Z; Song P; Guo X; Husain SZ; Hu G; Li L; Wen L
Biochim Biophys Acta Mol Basis Dis; 2022 Dec; 1868(12):166490. PubMed ID: 35841983
[TBL] [Abstract][Full Text] [Related]
6. Blockade of the Phagocytic Receptor MerTK on Tumor-Associated Macrophages Enhances P2X7R-Dependent STING Activation by Tumor-Derived cGAMP.
Zhou Y; Fei M; Zhang G; Liang WC; Lin W; Wu Y; Piskol R; Ridgway J; McNamara E; Huang H; Zhang J; Oh J; Patel JM; Jakubiak D; Lau J; Blackwood B; Bravo DD; Shi Y; Wang J; Hu HM; Lee WP; Jesudason R; Sangaraju D; Modrusan Z; Anderson KR; Warming S; Roose-Girma M; Yan M
Immunity; 2020 Feb; 52(2):357-373.e9. PubMed ID: 32049051
[TBL] [Abstract][Full Text] [Related]
7. MERTK Acts as a Costimulatory Receptor on Human CD8
Peeters MJW; Dulkeviciute D; Draghi A; Ritter C; Rahbech A; Skadborg SK; Seremet T; Carnaz Simões AM; Martinenaite E; Halldórsdóttir HR; Andersen MH; Olofsson GH; Svane IM; Rasmussen LJ; Met Ö; Becker JC; Donia M; Desler C; Thor Straten P
Cancer Immunol Res; 2019 Sep; 7(9):1472-1484. PubMed ID: 31266785
[TBL] [Abstract][Full Text] [Related]
8. Tissue-specific modifier alleles determine
Akalu YT; Mercau ME; Ansems M; Hughes LD; Nevin J; Alberto EJ; Liu XN; He LZ; Alvarado D; Keler T; Kong Y; Philbrick WM; Bosenberg M; Finnemann SC; Iavarone A; Lasorella A; Rothlin CV; Ghosh S
Elife; 2022 Aug; 11():. PubMed ID: 35969037
[TBL] [Abstract][Full Text] [Related]
9. Expression of TAM-R in Human Immune Cells and Unique Regulatory Function of MerTK in IL-10 Production by Tolerogenic DC.
Giroud P; Renaudineau S; Gudefin L; Calcei A; Menguy T; Rozan C; Mizrahi J; Caux C; Duong V; Valladeau-Guilemond J
Front Immunol; 2020; 11():564133. PubMed ID: 33101282
[TBL] [Abstract][Full Text] [Related]
10. MerTK inhibition in tumor leukocytes decreases tumor growth and metastasis.
Cook RS; Jacobsen KM; Wofford AM; DeRyckere D; Stanford J; Prieto AL; Redente E; Sandahl M; Hunter DM; Strunk KE; Graham DK; Earp HS
J Clin Invest; 2013 Aug; 123(8):3231-42. PubMed ID: 23867499
[TBL] [Abstract][Full Text] [Related]
11. MerTK expressing hepatic macrophages promote the resolution of inflammation in acute liver failure.
Triantafyllou E; Pop OT; Possamai LA; Wilhelm A; Liaskou E; Singanayagam A; Bernsmeier C; Khamri W; Petts G; Dargue R; Davies SP; Tickle J; Yuksel M; Patel VC; Abeles RD; Stamataki Z; Curbishley SM; Ma Y; Wilson ID; Coen M; Woollard KJ; Quaglia A; Wendon J; Thursz MR; Adams DH; Weston CJ; Antoniades CG
Gut; 2018 Feb; 67(2):333-347. PubMed ID: 28450389
[TBL] [Abstract][Full Text] [Related]
12. Dual Axl/MerTK inhibitor INCB081776 creates a proinflammatory tumor immune microenvironment and enhances anti-PDL1 efficacy in head and neck cancer.
Kostecki KL; Iida M; Wiley AL; Kimani S; Mehall B; Tetreault K; Alexandridis R; Yu M; Hong S; Salgia R; Bruce JY; Birge RB; Harari PM; Wheeler DL
Head Neck; 2023 May; 45(5):1255-1271. PubMed ID: 36939040
[TBL] [Abstract][Full Text] [Related]
13. Potential Oncogenic Effect of the MERTK-Dependent Apoptotic-Cell Clearance Pathway in Starry-Sky B-Cell Lymphoma.
Farnworth-McHugh S; Barth N; Melville L; Paterson M; Lynch C; Holland P; Dransfield I; Gregory C
Front Immunol; 2020; 11():1759. PubMed ID: 32973744
[TBL] [Abstract][Full Text] [Related]
14. MERTK inhibition alters the PD-1 axis and promotes anti-leukemia immunity.
Lee-Sherick AB; Jacobsen KM; Henry CJ; Huey MG; Parker RE; Page LS; Hill AA; Wang X; Frye SV; Earp HS; Jordan CT; DeRyckere D; Graham DK
JCI Insight; 2018 Nov; 3(21):. PubMed ID: 30385715
[TBL] [Abstract][Full Text] [Related]
15. MerTK as a therapeutic target in glioblastoma.
Wu J; Frady LN; Bash RE; Cohen SM; Schorzman AN; Su YT; Irvin DM; Zamboni WC; Wang X; Frye SV; Ewend MG; Sulman EP; Gilbert MR; Earp HS; Miller CR
Neuro Oncol; 2018 Jan; 20(1):92-102. PubMed ID: 28605477
[TBL] [Abstract][Full Text] [Related]
16. Regulation of bone homeostasis by MERTK and TYRO3.
Engelmann J; Zarrer J; Gensch V; Riecken K; Berenbrok N; Luu TV; Beitzen-Heineke A; Vargas-Delgado ME; Pantel K; Bokemeyer C; Bhamidipati S; Darwish IS; Masuda E; Burstyn-Cohen T; Alberto EJ; Ghosh S; Rothlin C; Hesse E; Taipaleenmäki H; Ben-Batalla I; Loges S
Nat Commun; 2022 Dec; 13(1):7689. PubMed ID: 36509738
[TBL] [Abstract][Full Text] [Related]
17. MERTK Promotes Resistance to Irreversible EGFR Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancers Expressing Wild-type
Yan D; Parker RE; Wang X; Frye SV; Earp HS; DeRyckere D; Graham DK
Clin Cancer Res; 2018 Dec; 24(24):6523-6535. PubMed ID: 30194074
[TBL] [Abstract][Full Text] [Related]
18. TYRO3 blockade enhances anti-PD-1 therapy response by modulating expression of CCN1 in tumor microenvironment.
Park M; Kuen DS; Park J; Choi M; Kim Y; Roh EC; Choi YJ; Kim YG; Chung Y; Cho SY; Kang KW
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36693679
[TBL] [Abstract][Full Text] [Related]
19. Mer Tyrosine Kinase Regulates Disseminated Prostate Cancer Cellular Dormancy.
Cackowski FC; Eber MR; Rhee J; Decker AM; Yumoto K; Berry JE; Lee E; Shiozawa Y; Jung Y; Aguirre-Ghiso JA; Taichman RS
J Cell Biochem; 2017 Apr; 118(4):891-902. PubMed ID: 27753136
[TBL] [Abstract][Full Text] [Related]
20. MerTK mediates STAT3-KRAS/SRC-signaling axis for glioma stem cell maintenance.
Eom H; Kaushik N; Yoo KC; Shim JK; Kwon M; Choi MY; Yoon T; Kang SG; Lee SJ
Artif Cells Nanomed Biotechnol; 2018; 46(sup2):87-95. PubMed ID: 29553850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
